Investors knocked back Valeant Pharmaceuticals International Inc. shares Monday after the company said it is shifting away from some of the key business strategies that have propelled its success, amid criticism of high drug prices.
The Quebec-based drug maker outlined a number of changes to its vaunted business model of growing through acquisitions instead of investing in research and development, saying it is spending more on R&D.
Read Full Article »